Know Cancer

forgot password

A Clinical Study To Evaluate the Safety and Efficacy of MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication Techniques

Phase 3
18 Years
Not Enrolling
Uterine Leiomyoma, Uterine Fibroids

Thank you

Trial Information

A Clinical Study To Evaluate the Safety and Efficacy of MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication Techniques

Uterine leiomyoma (fibroids) are the most common neoplasms of the female pelvis. These
benign tumors are generally oval in shape, and often highly vascular. On T2 weighted MR
imaging exams, or T1 exams with contrast, uterine fibroids are easily identifiable. They
occur in 20-25% of women of reproductive age and can cause a variety of problems generally
described as either bleeding or mass effects from the fibroid. InSightec has developed an
Enhanced Sonication (ES) technique for the ablation of these fibroids. This mode of tissue
ablation has been added to the already FDA approved ExAblate system. The goal of this ES
technique is to provide an additional treatment tool that will enhance the treatment effect
without additional risks while preserving ALL clinical features of the current commercially
approved version.

Inclusion Criteria:

1. Women age 18 or older, who present with symptomatic fibroids

2. Women who have given written informed consent

3. Women who are able and willing to attend all study visits.

4. Patient is pre or peri-menopausal (within 12 months of last menstrual period).

5. Able to communicate sensations during the ExAblate procedure.

6. Uterine fibroids, which are device accessible (i.e., positioned in the uterus such
that they can be accessed without being shielded by bowel or bone).

7. Fibroids(s) clearly visible on non-contrast MRI.

Exclusion Criteria:

1. Women who are pregnant, as confirmed by serum test at time of screening, or urine
pregnancy test on the day of treatment

2. Patient who desire to become pregnant in the future.

3. Patients who are breast-feeding.

4. Patients with an active pelvic inflammatory disease (PID)

5. Active local or systemic infection

6. Metallic implants that are incompatible with MRI

7. Known intolerance to the MRI contrast agent (e.g. Gadolinium or Magnevist)

8. Severe claustrophobia that would prevent completion of procedure in the MR unit.

9. Extensive abdominal scarring in the beam pass or dermoid cyst of the ovary anywhere
in the treatment path.

10. Known or suspected pelvic carcinoma or pre-malignant conditions, including sarcoma
and adenomatous hyperplasia.

11. Pedunculated fibroids.

12. Intrauterine device (IUD) anywhere in the treatment path

13. Undiagnosed vaginal bleeding.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The primary end point is to determine the safety of the new Enhanced Sonication technique and assure no new safety issues are introduced.

Outcome Time Frame:

Within 1 month of treatment

Safety Issue:


Principal Investigator

Anne Roberts, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of California, San Diego


United States: Food and Drug Administration

Study ID:




Start Date:

October 2006

Completion Date:

August 2008

Related Keywords:

  • Uterine Leiomyoma
  • Uterine Fibroids
  • Fibroids
  • leiomyoma
  • neoplasm
  • benign tumors
  • Leiomyoma
  • Myofibroma



University of California at San DiegoLa Jolla, California  92093
Lahey ClinicBurlington, Massachusetts  01805
Cornell VascularNew York, New York  10022
KNIKalamazoo, Michigan  49048